Abstract: A cat litter additive for detecting pH value of cat urine, comprising starch, microcrystalline cellulose, organic solvents, binders, pH indicators, pH adjusters and water; Amount of the starch is 30-200 parts, the microcrystalline cellulose is 20-100 parts, the organic solvent is 10-60 parts, the binder is 1-20 parts, the pH indicator is 0.05-2 parts, the pH adjuster is 0.01-10 parts, the water is 0-100 parts; a preparation method for detecting the pH value of cat urine cat litter additive comprises five steps. The product obtained by the present invention can fit well the normal urine pH value range of cat, if the cat urine pH is located at 5.5-7.5 the indicator shows light green to dark green; if the pH value is lower than 5.5, the indicator shows orange yellow to yellow, if the PH value is greater than 7.5, the indicator shows cyan to blue.

Abstract: The present invention relates to novel forms of Compound I, preparation thereof, pharmaceutical composition containing the same and use thereof, wherein, the compound is (S)-5-((1-(3-(5-methyl-3-(trifluoromethyl)-8,9-dihydropyrido[3?,2?:4,5]pyrrolo[1,2-a]pyrazin-7(6H)-yl)-3-oxopropoxy)propan-2-yl)oxy)-4-(trifluoromethyl)pyridazin-3(2H)-one.

Abstract: The invention relates to novel glutamine analogs, a composition containing the glutamine analogs and the use thereof.

Abstract: Pyrido[3,2-d]pyrimidine compounds are provided that are potent HPK1 inhibitors that are useful to treat or prevent cancer and/or inflammatory and/or autoimmune diseases or symptoms thereof in mammals, particularly humans. The compounds disclosed herein have a chemical structure of the general formula (I) and (II) or a prodrug or pharmaceutically acceptable salt of any of the foregoing including mixtures thereof in all ratios.

Abstract: The present invention provides recombinant bispecific antibodies designed to bind to a surface antigen on target cells and to an activating component on immune cells such as T cells. The bispecific antibodies comprise two polypeptide chains that contain Fv and Fab as antigen-binding fragments and a modified Fc region to facilitate heterodimer formation. In one embodiment, the bispecific antibodies further comprise protease cleavage sites and/or motifs that would cause steric occlusion of the antigen binding sites so that the antibodies would be activated only in a specific environment, e.g. in the vicinity of a tumor. In another embodiment, the bispecific antibodies comprise modified sequences that confer reduced binding affinity to CDS and/or cross-reactive binding to CDS on cells from different species.

Abstract: The present invention provides recombinant bispecific antibodies designed to bind to a surface antigen on target cells and to an activating component on immune cells such as T cells. The bispecific antibodies comprise two polypeptide chains that contain Fv and Fab as antigen¬binding fragments and a modified Fc region to facilitate heterodimer formation. In one embodiment, the bispecific antibodies further comprise protease cleavage sites and/or motifs that would cause steric occlusion of the antigen binding sites so that the antibodies would be activated only in a specific environment, e.g. in the vicinity of a tumor. In another embodiment, the bispecific antibodies comprise modified sequences that confer reduced binding affinity to CDS and/or cross-reactive binding to CDS on cells from different species.

Abstract: A bi-functional, proteolysis-targeting chimera (PROTAC) agent is provided for the modulation of transcriptional factor FOXP3 and associated regulatory T cells. The agent contains an inhibitory peptide of FOXP3 covalently bound through a linker to a ubiquitin ligase binding moiety. The agent binds FOXP3 and recruits an E3 ubiquitin ligase, and thereby bringing FOXP3 in proximity to the E3 ubiquitin ligase for ubiquitination and degradation of the FOXP3. Methods of preparation and use of the agent are also provided.

Abstract: The present disclosure discloses a gradient single-crystal positive electrode material, which has a chemical formula of LiNixCoyA1-x-yO2@mLiaZbOc, wherein 0<x<1, 0<y<1, 0<x+y<1, 0<m<0.05, 0.3<a?10, 1?b<4, and 1?c<15, A is at least one of Mn, Zr, Sr, Ba, W, Ti, Al, Mg, Y, and Nb, and Z is at least one of B, Al, Co, W, Ti, Zr, and Si. The atomic ratio of the content of Co on the surface of the single-crystal positive electrode material particle to the content of Ni+Co+A on the surface is greater than 0.4 and less than 0.8, and the atomic ratio of Co at a depth 10% of the radius from the surface of the single crystal positive electrode material particle is not less than 0.3; and the single-crystal positive electrode material particle has a roundness of greater than 0.4, and is free from sharp corners.

Abstract: Provided are K-Ras mutant protein inhibitors of formula (I), a composition containing the same and the use thereof.

Abstract: A Compound of formula (I) or (II), a stereoisomer thereof, an atropisomer, a pharmaceutically acceptable salt thereof, a pharmaceutically acceptable salt of the stereoisomer, a pharmaceutically acceptable salt of the atropisomer, a prodrug thereof, a deuterated molecule thereof or a conjugated form thereof is disclosed:

Abstract: Disclosed are tricyclic compounds as bromodomain and extra-terminal (BET) inhibitors which are shown as formula I, their synthesis and their use for treating diseases. More particularly, disclosed are fused heterocyclic derivatives useful as inhibitors of BET, methods for producing such compounds and methods for treating diseases and conditions wherein inhibition of one or more BET bromodomains provides a benefit.

Abstract: Provided are compounds of formula (I) which can bind to mutant p53 and restore the ability of the p53 mutant to bind DNA and activate downstream effectors involved in tumor suppression. Also provided are pharmaceutical compositions comprising the compounds, methods of preparing the compounds and the use in the manufacture of medicaments for preventing or treating a disease or condition related to p53 mutants.

Abstract: Provided herein are salts of the compound 1 and new poly morph forms thereof, pharmaceutical composition including the compound 1 and new polymorph forms thereof, and methods of preparing them and using them.